RSS   Newsletter   Contact   Advertise with us

Nordic Nanovector appoints Lisa Rojkjaer as chief medical officer

Staff Writer | Oslo, Norway | November 16, 2016
Nordic NanovectorNovember 16, 2016, Oslo, Norway - Nordic Nanovector ASA, a biotechnology company, announces that Lisa Rojkjaer has joined the company as chief medical officer and as a member of the executive management team.
Dr. Rojkjaer is a board-certified haematologist with more than 15 years of global and regional clinical development and medical affairs expertise in the biotech and pharma industries, and has extensive experience in the development of both biologics and small molecules in haematology and immunology.

Dr. Rojkjaer joins Nordic Nanovector from Novartis Pharmaceuticals where she held the position of Global Clinical Program Head, Oncology Global Development.

Her previous roles also include CMO at Molecular Partners (Switzerland), Vice President, Head of Clinical Development at Morphosys AG (Germany), and Head of Global Medical Affairs, Biopharmaceuticals and Director of Clinical Development, Hematology in the US for Novo Nordisk.

Dr. Rojkjaer holds a medical degree from the University of Toronto and received board certification in both internal medicine and hematology.